Site has a capital investment program of ~$30 million spent or committed over the last three years to expand capabilities and improve operational efficiencies
New block enhances the company's global capabilities in Oral Solid Dosage (OSD) Forms, increasing total plant capacity to 4.5 billion doses
It is part of the company's CAD $30 million capital investment in the Aurora, Canada site
The brand has added a range of exciting new products especially formulated for oily skin.
In the first phase of the Grangemouth site expansion, two new ADC manufacturing suites, operational by Q3 2023, will be added to the existing three
Market data indicates that more than twenty percent of the new chemical entities being developed use roller compaction technology in their development and commercialization
The investment in Yapan Bio allows Piramal Pharma Solutions to broaden its service offerings in the fast-growing biologics CDMO space
This acquisition marks PPS’ foray into the development and manufacturing of peptide APIs
The launch of Chlorpromazine Hydrochloride for Injection is the latest in a series of recent product launches from Piramal Critical Care
Subscribe To Our Newsletter & Stay Updated
